Keeping Pace with the Evolving Treatment Management of MS to Improve Patient Outcomes
A 3-Track CE Webcast Series
Track 1: Treatment Considerations in Special Populations: Addressing Health Disparities in MS
Track 2: Evolving Treatment Guidelines in MS: Safety Profile Updates in the Era of COVID-19
Track 3: Latest Considerations Around the Impact of MS Treatments on Immune Response

Learn About:

The benefit and risk profile of disease modifying therapies.
The implications of disease modifying therapies on the immune system and vaccine response.
Key health disparities that can impact access to care.
Strategies to address health disparities.

Expert Faculty Presenters:


	Léorah Freeman, MD, PhD (chair) Assistant Professor of Neurology Dell Medical School The University of Texas at Austin Click here for biography

	Heidi Crayton, MD (Track 1) Clinical Neurologist MS Center of Greater Washington Click here for biography

	Matthew McCoyd, MD (Track 2) Neurology Residency Program Director Associate Professor Loyola Medicine Click here for biography

	Jacqueline F. Rosenthal, MD (Track 3) Neurologist Andrew C. Carlos Multiple Sclerosis Institute Shepherd Center Click here for biography

MS Community Representatives:

	Teresa Wright-Johnson (Track 1)

	Damian Washington (Track 2)

	Julian Gamboa (Track 3)

Target Audience
The target audience consists of neurologists, nurse practitioners & nurses, pharmacists, physician assistants, and other health care professionals involved in treatment and management of patients with MS.

Statement of Need/Program Overview
More than a dozen disease-modifying therapies (DMTs) are available for the treatment of MS with several additional novel therapies in late-stage development. Early diagnosis and aggressive treatment are essential to minimize the MS disease burden and limit use of limited health care resources. The continually evolving MS treatment landscape, the impact of COVID-19, and addressing health disparities in the MS community accentuates the need for increased disease and therapeutic knowledge amongst MS advanced practice providers in order to optimize clinical outcomes, reduce treatment variability, and increase patient engagement in their own care.

Educational Objectives
After completing this activity, the participant should be better able to:

Track 1

Describe key health disparities that can impact access to multiple sclerosis (MS) treatment
Employ short and long-term strategies to address health disparities in patients with MS

Track 2

Review current evidence-based recommendations for initial and follow-on MS therapy
Describe the importance of early and ongoing treatment of MS considering the benefit and risk profile of disease modifying therapies taking into account the challenges presented by the COVID-19 pandemic

Track 3

Describe the short and long-term implications of DMTs on the immune system and vaccine response in people with MS
Assess strategies to increase patient awareness of the need for the full spectrum of indicated vaccinations

Accreditation Statement

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Multiple Sclerosis Association of America (MSAA), Postgraduate Institute for Medicine, and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Track 1: 1.0 CME credit
Track 2: 1.0 CME credit
Track 3: 1.0 CME credit

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for a maximum of 3.0 contact hour(s) (0.3 CEUs) of the Accreditation Council for Pharmacy Education.

Track 1:

UAN: JA4008162-9999-22-314-L01-P
Contact Hour: 1.0
Activity Type: Knowledge-based

Track 2:

UAN: JA4008162-9999-22-315-L01-P
Contact Hour: 1.0
Activity Type: Knowledge-based

Track 3:

UAN: JA4008162-9999-22-316-L01-P
Contact Hour: 1.0
Activity Type: Knowledge-based

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.0 contact hours.

Track 1: 1.0 CME credit
Track 2: 1.0 CME credit
Track 3: 1.0 CME credit

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

*Name of Working Group Members/Planners*	*Reported Financial Relationship*
Léorah Freeman, MD, PhD	Consulting Fees (e.g., advisory boards): Genentech, Inc; Novartis;EMD Serono; Bristol Myers Squibb; TG Therapeutics
Heidi Crayton, MD	Consulting Fees (e.g., advisory boards): Biogen, Sanofi, EMD Serono, Janssen, Bristol Myers Squibb, Novartis Fees for Non-CE Services Received Directly from an ineligible Entity or their Agents (e.g., speakers' bureaus): Biogen, Sanofi, EMD Serono, Janssen, Bristol Myers Squibb Contracted Research: Biogen, Sanofi, EMD Serono, Atara, Anokion, Novartis
Matthew McCoyd, MD	Coming soon
Jacqueline F. Rosenthal, MD	Consulting Fees (e.g., advisory boards): EMD Serono, TG Therapeutics, Horizon Therapeutics
Teresa Wright-Johnson	No financial interest/relationships relating to the topic of this activity
Damian Washington	No financial interest/relationships relating to the topic of this activity
Julian Gamboa	No financial interest/relationships relating to the topic of this activity

The PIM planners and managers have nothing to disclose.
The MSAA planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.